{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Complete response (CR)"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Near complete response (nCR)"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Very good partial response (VGPR)"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Partial response (PR)"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Stable disease (SD)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Disease response using Blade Multiple Myeloma Response Criteria in newly diagnosed (Cohort II) patients who completed at least one cycle of treatment. There were 24 evaluable patients in Cohort II.","groups":[{"description":"Patients with newly diagnosed multiple myeloma receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\ncyclophosphamide: Given IV or PO\n\npegylated liposomal doxorubicin hydrochloride: Given IV\n\nbortezomib: Given IV\n\ndexamethasone: Given IV or PO","id":"OG000","title":"Newly Diagnosed Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Newly diagnosed patients (cohort II)","reportingStatus":"POSTED","timeFrame":"up to 28 days after last cycle of treatment","title":"Disease Response Rate (Cohort II)","type":"PRIMARY","unitOfMeasure":"Participants"}